Top

Published in:

01-02-2015 | DIAGNOSTICS AND ENVIRONMENTAL FACTORS

Lupus and leprosy: beyond the coincidence

Authors: F. M. Ribeiro, V. E. Gomez, E. M. N. Albuquerque, E. M. Klumb, Y. Shoenfeld

Published in: Immunologic Research | Issue 1-2/2015

Abstract

Systemic lupus erythematous (SLE) is an autoimmune disease that presents an increased susceptibility to infections which may trigger reactivation. Disease flares have been mostly associated with parvovirus B19, cytomegalovirus, EBV and Mycobacterium tuberculosis infections, but it is probable that many other agents may also induce innate and adaptive immune system stimulation including the production of autoantibodies as ANA, anti nDNA and anti-ß2-GPI mainly in lepromatous leprosy. Mycobacterium leprae not only may determine symptoms that mimic lupus flares, including autoantibodies production, but could also act as a trigger for lupus reactivation; however, its association is still not fully explored. As demonstrated for tuberculosis, it is quite possible that molecular mimicry may also be involved in the interface of these two diseases. Some studies reported shared epitopes among idiotypes derived from 8E7 and TH9 lepromatous antibodies and those obtained from SLE patients, and it could partially explain the triggering phenomenon of SLE caused by M. leprae. We report and discuss three Brazilian patients whose disease was inactive and presented disease flares concurrently with the diagnosis of leprosy.

Hsu TC, Tsay GJ. Human parvovirus B19 infection in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2001;40:152–7.CrossRef

Hemauer A, Beckenlehner K, Wolf H, Lang B, Modrow S. Acute parvovirus B19 infection in connection with a flare of systemic lupus erythematodes in a female patient. J Clin Virol. 1999;14:73–7.PubMedCrossRef

Goddard GZ, Shoenfeld Y. Infections and SLE. Autoimmunity. 2005;38:473–85.CrossRef

Hayashi T, Lee S, Ogasawara H, Sekigawa I. Exacerbation of systemic lupus erythematosus related to cytomegalovirus infection. Lupus. 1998;7:561–4.PubMedCrossRef

Francis L, Perl A. Infection in systemic lupus erythematosus: friend or foe? Int J Clin Rheumtol. 2010;5:59–74.PubMedCentralPubMedCrossRef

Ribeiro FM, Szyper-Kravitz M, Klumb EM, et al. Can lupus flares be associated with tuberculosis infection? Clin Rev Allergy Immunol. 2010;38:163–8.PubMedCrossRef

Shoenfeld Y, Isenberg DA. Mycobacteria and autoimmunity. Immunol Today. 1988;9:178–81.PubMedCrossRef

Sela O, El-Roeiy A, DA Isenberg J, et al. A common anti-DNA antibody idiotype in sera of patients with active pulmonary tuberculosis. Arthritis Rheum. 1987;30:50–5.PubMedCrossRef

Carducci R, Teralbini CGL, Tak CG. Autoantibodies in leprosy. Int J Lepr. 1978;58:171–5.

10.

Guedes Barbosa LS, Gilbrut B, Shoenfeld Y, Sheinberg MA. Autoantibodies in leprosy sera. Clin Rheumatol. 1996;15:26–8.PubMedCrossRef

11.

Eichelmann K, González González SE, Salas-Alanis JC, Ocampo-Candiani J. Leprosy. An update: definition, pathogenesis, classification, diagnosis, and treatment. Actas Dermosifiliogr. 2013;104:554–63.PubMedCrossRef

12.

Global leprosy situation. Wkly Epidemiol Rec. 2010;85:337–48.

13.

Gulia A, Fried I, Massone C. New insights in the pathogenesis and genetics of leprosy. F1000 Medicine Reports. 2010;27:2.

14.

Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL. The continuing challenges of leprosy. Clin Microbiol Rev. 2006;19:338–81.PubMedCentralPubMedCrossRef

15.

Demangel C, Britton WJ. Interaction of dendritic cells with mycobacteria: where the action starts. Immunol Cell Biol. 2000;78:318–24.PubMedCrossRef

16.

Rodrigues LS, da Silva Maeda E, et al. Mycobacterium leprae induces insulin-like growth factor and promotes survival of Schwann cells upon serum withdrawal. Cell Microbiol. 2010;12:42–54.PubMedCrossRef

17.

Scollard DM, Smith T, Bhoopat L, Theetranont C, Rangdaeng S, Morens DM. Epidemiologic characteristics of leprosy reactions. Int J Lepr Other Mycobact Dis. 1994;1994(62):559–67.

18.

Kumar B, Dogra S, Kaur I. Epidemiological characteristics of leprosy reactions: 15 years experience from North India. Int J Lepr Other Mycobact Dis. 2004;72:125–33.PubMedCrossRef

19.

Salvi S, Chopra A. Leprosy in a rheumatology setting: a challenging mimic to expose. Clin Rheumatol. 2013;32:1557–63.PubMedCentralPubMedCrossRef

20.

Teixeira Júnior GJ, Silva CEF, Magalhães V. Application of the diagnostic criteria for systemic lupus erythematosus to patients with multibacillary leprosy. Rev Soc Bras Med Trop. 2011;44:85–90.PubMedCrossRef

21.

la Torre Garcia-de. I. Autoimmune phenomena in leprosy, particularly antinuclear antibodies and rheumatoid factor. J Rheumatol. 1993;20:900–3.

22.

Kroumpouzos G, Vareltzidis A, Konstadoulakis MM, et al. Evaluation of the autoimmune response in leprosy. Lepr Rev. 1993;64:199–207.PubMed

23.

Miller RA, Wener MH, Harnisch JP, Gilliland BC. The limited spectrum of antinuclear antibodies in leprosy. J Rheumatol. 1987;14:108–10.PubMed

24.

Sharma VK, Saha K, Sehgal VN. Serum immunoglobulins and autoantibodies during and after erythema nodosum leprosum (ENL). Int J Lepr Other Mycobact Dis. 1982;50:159–63.PubMed

25.

Masala C, Amendolea MA, Nuti M, Riccarducci R, Tarabini CG, Tarabini CG. Autoanibodies in leprosy. Int J Lepr Other Mycobac Dis. 1979;47:171–5.

26.

Guedes-Barbosa LS, Gilbrut B, Shoenfeld Y, Scheinberg MA. Autoantibodies in leprosy sera. Clin Rheumatol. 1996;15:26–8.PubMedCrossRef

27.

Zandman-Goddard G, Blank M, Shoenfeld Y. Antiphospholipid antibodies and infections-drugs. In: Asherson RA, Cervera R, Piette JC, Shoenfeld Y, editors. The antiphospholipid syndrome II. Amsterdan: Elsevier Science; 2002. p. 343–60.CrossRef

28.

Elbeialy A, Strassburger-Lorna K, Altsumi T, et al. Antiphospholipid antibodies in leprotic patients: a correlation with disease manifestation. Clin Exp Rheumatol. 2000;18:492–4.PubMed

29.

Loizou S, Singh S, Wypkema E, Asherson RA. Anticardiolipin anti- beta2-glycoprotein I and antiprothrombin antibodies in black South African patients with infectious disease. Ann Rheum Dis. 2003;62:1106–11.PubMedCentralPubMedCrossRef

30.

de Laranaga GF, Forastiero RR, Martinuzzo ME, et al. High prevalence of antiphospholipid antibodies in leprosy: evaluation of antigen reactivity. Lupus. 2000;9:594–600.CrossRef

31.

Bonfa E, Llovet R, Scheinberg M, de Souza JM, Elkon KB. Comparison between autoantibodies in malaria and leprosy with lupus. Clin Exp Immunol. 1987;70:529–37.PubMedCentralPubMed

32.

Hojnik M, Gilburd B, Ziporen L, et al. Anticardiolipin antibodies in infections are heterogeneous in their dependency on ß2-GPI: analysis of anticardiolipina antibodies in leprosy. Lupus. 1994;3:515–21.PubMedCrossRef

33.

Levy RA, Pierangeli SA, Espinola RG. Antiphospholipid beta-2 glycoprotein I dependency assay to determine antibody pathogenicity. Arthritis Rheuma. 2000;43(suppl):I476.

34.

Ribeiro SLE, Pereira HLA, Silva NP, Souza AWS, Sato EI. Anti- ß2 glycoprotein I antibodies are highly prevalent in a large number of Brazilian leprosy patients. Acta Reumatol Port. 2011;36:30–7.PubMed

35.

Asherson RA, Shoenfeld Y. The role of infections in the pathogenesis of catasthrophic antiphospholipid syndrome—molecular mimicry? J Rheumatol. 2000;27:12–4.PubMed

36.

Shoenfeld Y, Isenberg DA. Mycobacteria and autoimmunity. Immunol Today. 1988;9:178–81.PubMedCrossRef

37.

Shoenfeld Y, Vilner Y, Coates AR, et al. Monoclonal anti- tuberculosis antibodies react with DNA and monoclonal anti- DNA autoantibodies react with Mycobacterium tuberculosis. Clin Exp Immunol. 1986;66:255–61.PubMedCentralPubMed

38.

Amital-Teplizic H, Avinoach I, Coates AR, Kooperman O, Blank M, Shoenfeld Y. Binding of monoclonal anti-DNA and anti-TB glycolipids to brain tissue. Autoimmunity. 1989;4:277–87.CrossRef

39.

Sela O, El-Roeiy A, Isenberg DA, et al. A common anti-DNA antibody idiotype in sera of patients with active pulmonary tuberculosis. Arthritis Rheum. 1987;30:50–5.PubMedCrossRef

40.

Mackworth-Young CG, Sabbaga J, Schwartz RS. Idiotypic markers of polyclonal B cell activation. Public idiotypes shared by monoclonal antibodies derived from patients with systemic lupus erythematosus or leprosy. J Clin Invest. 1987;79:572–81.PubMedCentralPubMedCrossRef

41.

Mackworth-Young CG. Cross-reactive idiotypes in sera from patients with leprosy, lupus and Lyme disease and from healthy individuals. Clin Exp Immunol. 1990;79:78–82.PubMedCentralPubMedCrossRef

42.

Mackworth-Young CG, Cairns E, Sabbaga J, et al. Comparative study of idiotypes on monoclonal antibodies derived from patients with lupus and leprosy and from normal individuals. J Autoimmunity. 1990;3:415–9.CrossRef

Title: Lupus and leprosy: beyond the coincidence
Authors: F. M. Ribeiro
V. E. Gomez
E. M. N. Albuquerque
E. M. Klumb
Y. Shoenfeld
Publication date: 01-02-2015
Publisher: Springer US
Published in: Immunologic Research / Issue 1-2/2015
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-014-8596-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Lupus and leprosy: beyond the coincidence

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1-2/2015

Vitamin D in primary biliary cirrhosis, a plausible marker of advanced disease

Cutting edge data in autoimmunity: as presented in the 9th international congress of autoimmunity

The epidemiological profile of ASIA syndrome after HPV vaccination: an evaluation based on the Vaccine Adverse Event Reporting Systems

Autoimmune diagnostics: the technology, the strategy and the clinical governance

Clinical performance evaluation of a novel, automated chemiluminescent immunoassay, QUANTA Flash CTD Screen Plus

Hepatopulmonary syndrome associated with visceral leishmaniasis